BHVN250117P80000
- 0.00
- 0.000.00%
Biohaven Newsroom
Piper Sandler Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $76
Piper Sandler Remains a Buy on Biohaven Ltd. (BHVN)
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $63
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $63
H.C. Wainwright Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $56 to $69
Biohaven Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $61
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Biohaven Price Target Raised to $61.00/Share From $58.00 by RBC Capital
Biohaven Analyst Ratings
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Biohaven Ltd.: Buy Rating Affirmed Amid Promising Drug Prospects and Strategic FDA Engagement
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)